Monocyte Activation Test in 384-Well Plates for Low-Reagent Throughput
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pyrogen and endotoxin detection assays, such as the rabbit pyrogen test and limulus amebocyte lysate assay, are costly, time-consuming, and require the use of animals, with the limulus amebocyte lysate assay being limited to Gram-negative bacteria and prone to false-positives, while existing monocyte activation tests have low throughput, high reagent consumption, and are constrained by regulatory guidelines.
Innovation Solution
A method involving a monocyte activation test using peripheral blood mononuclear cells (PBMCs) in an incubation medium with a volume of at most 175 μL per sample, conducted in a 384-well plate, to detect pyrogens and endotoxins, allowing for high-throughput, reduced reagent consumption, and adherence to regulatory standards.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional monocyte activation test protocols are used, then regulatory compliance is ensured, but throughput is low and reagent consumption is high
Solution Approach 1:
The patent segments the assay into smaller individual wells within a 384-well plate format, allowing parallel processing of multiple samples simultaneously. This segmentation enables high-throughput testing while maintaining regulatory compliance through standardized protocol adherence in each individual well.
Solution Approach 2:
The patent changes critical parameters including reducing incubation medium volume to 50-175 μL per well, adjusting cell density to 10,000-500,000 cells/cm², and modifying incubation time to 16-72 hours. These parameter optimizations reduce reagent consumption while maintaining assay sensitivity and regulatory compliance.
2Quantity of substance
If traditional monocyte activation test protocols are used, then regulatory compliance is ensured, but reagent consumption is high and costs are high
Solution Approach 1:
By dividing the assay into multiple small wells (384-well plate format) rather than using fewer large wells, the patent segments reagents into smaller portions. This segmentation reduces total reagent consumption and associated costs while maintaining the ability to process multiple samples in parallel.
Solution Approach 2:
The patent optimizes reagent consumption by changing medium volume to 50-175 μL per well, adjusting cell density parameters, and modifying incubation conditions. These parameter changes directly reduce reagent requirements and associated costs while maintaining assay validity and regulatory compliance.
3Reliability
If conventional detection methods are used, then detection capability is maintained, but the tests are time-consuming and require animals
Solution Approach 1:
The patent replaces traditional mechanical/physical detection methods with molecular detection techniques, specifically measuring cytokine production (IL-6, IL-1beta, IL-8, TNF-alpha) through biochemical assays. This substitution eliminates the need for animal testing while maintaining detection capability and reducing test time through automated sampling and analysis.
Solution Approach 2:
The patent optimizes incubation time parameters to 16-72 hours, which balances detection sensitivity with time efficiency. By carefully controlling this parameter along with cell density and medium composition, the patent achieves reliable detection without excessive test time or animal requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high prediction capacity with low variability and reduced costs, enabling efficient detection of pyrogens and endotoxins in various samples, including pharmaceutical compositions and medical devices, while adhering to animal-free and regulatory guidelines.
Implementation Method 1
The MAT is a test which is governed by specific regulatory guidelines for sample preparation, testing, and analysis of results, established in the European Pharmacopoeia... determining the response of the PBMCs, wherein the incubation medium has a volume of at most 175 μL per sample
Implementation Method 2
The response of the PBMCs that is determined is the excretion of an inflammatory cytokine such as IL-6, IL-1beta, IL-8, TNF-alpha, MCP-1, IL-10, IFN-alpha, IFN-beta, IFN-gamma, IFN-lambda
Data Source
AI summary
The present invention is in the field of in vitro assays, particularly to detect pyrogens. The invention provides improved methods for animal-free approaches by providing an improved monocyte activation test. The improved test allows for reduced consumption of reagents and for improved throughput.